Alimentary Pharmacology & Therapeutics

Does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?
pp. 1843-1849(7)
Authors: Bebb, J. R.; Logan, R. P. H.

Spontaneous bacterial peritonitis—diagnosis, treatment and prevention
pp. 1851-1859(9)
Authors: Mowat, C.; Stanley, A. J.

Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease
pp. 1861-1866(6)
Authors: Goodgame, R. W.; Kimball, K.; Akram, S.; Ike, E.; Ou, C.-N.; Sutton, F.; Graham, D.

Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial
pp. 1867-1873(7)
Authors: Hawkes, N. D.; Richardson, C.; Ch'Ng, C. L.; Green, J. T.; Evans, B. K.; Williams, J.; Rhodes, P.; Rhodes, J.; Swift, G. L.; Thomas, G. A. O.; Hawthorne, A. B.; Kingham, J. G. C.; Mayberry, J. F.

Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study
pp. 1875-1882(8)
Authors: Xia, H. H.-X.; Wong, B. C. Y.; Wong, K. W.; Wong, S. Y.; Wong, W. M.; Lai, K. C.; Hu, W. H. C.; Chan, C. K.; Lam, S. K.

Methicillin-resistant Staphylococcus aureus infection of percutaneous endoscopic gastrostomy sites
pp. 1883-1888(6)
Authors: Hull, M.; Beane, A.; Bowen, J.; Settle, C.

Systematic review: the use of somatostatin or octreotide in refractory diarrhoea
pp. 1889-1897(9)
Authors: Szilagyi, A.; Shrier, I.

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis
pp. 1899-1905(7)
Authors: Chan, H. L.-Y.; Tang, J.-L.; Tam, W.; Sung, J. J.-Y.

Reflux symptoms are associated with psychiatric disease
pp. 1907-1912(6)
Authors: Avidan, B.; Sonnenberg, A.; Giblovich, H.; Sontag, S. J.

Dysfunction of oesophageal motility in Helicobacter pylori-infected patients with reflux oesophagitis
pp. 1913-1919(7)
Authors: Wu, J. C. Y.; Lai, A. C. W.; Wong, S. K. H.; Chan, F. K. L.; Leung, W.-K.; Sung, J. J. Y.

Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia
pp. 1921-1928(8)
Authors: Schwartz, M. P.; Samsom, M.; Van Berge Henegouwen, G. P.; Smout, A. J. P. M.

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH
pp. 1929-1937(9)
Authors: Shirai, N.; Furuta, T.; Moriyama, Y.; Okochi, H.; Kobayashi, K.; Takashima, M.; Xiao, F.; Kosuge, K.; Nakagawa, K.; Hanai, H.; Chiba, K.; Ohashi, K.; Ishizaki, T.

Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage
pp. 1939-1947(9)
Authors: Sharma, V. K.; Sahai, A. V.; Corder, F. A.; Howden, C. W.

A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer
pp. 1949-1958(10)
Authors: Leodolter, A.; Kulig, M.; Brasch, H.; Meyer-Sabellek, W.; Willich, S. N.; Malfertheiner, P.

Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection
pp. 1959-1965(7)
Authors: Wong, B. C. Y.; Wong, W. M.; Yee, Y. K.; Hung, W. K.; Yip, A. W. C.; Szeto, M. L.; Li, K. F.; Lau, P.; Fung, F. M. Y.; Tong, T. S. M.; Lai, K. C.; Hu, W. H. C.; Yuen, M. F.; Hui, C. K.; Lam, S. K.

Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection
pp. 1967-1973(7)
Authors: Giannini, E.; Fasoli, A.; Borro, P.; Chiarbonello, B.; Malfatti, F.; Romagnoli, P.; Botta, F.; Testa, E.; Fumagalli, A.; Polegato, S.; Savarino, V.; Testa, R.

One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study
pp. 1975-1979(5)
Authors: Lu, H.; Zhang, D.-Z.; Hu, P.-J.; Li, Z.-S.; Lu, X.-H.; Fang, X.-C.; Xiao, S.-D.

Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model
pp. 1981-1988(8)
Authors: Smith, A. M.; Morris, T.; Justin, T.; Michaeli, D.; Watson, S. A.

Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis
pp. 1989-1999(11)
Authors: Carrier, J.; Aghdassi, E.; Platt, I.; Cullen, J.; Allard, J. P.

Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats
pp. 2001-2008(8)
Authors: Tibble, J.; Sigthorsson, G.; Caldwell, C.; Palmer, R. H.; Bjarnason, I.

A 3.0-kDa low molecular weight heparin promotes gastric ulcer healing in rats
pp. 2009-2017(9)
Authors: Li, Y.; Shin, V. Y.; Cheuk, C. Y.; Liu, E. S. L.; Cho, C. H.

Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat
pp. 2019-2025(7)
Authors: Miller-Larsson, A.; Gustafsson, B.; Persson, C. G. A.; Brattsand, R.

Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat
pp. 2027-2039(13)
Authors: Gálvez, J.; Coelho, G.; Crespo, M. E.; Cruz, T.; Rodríguez-Cabezas, M. E.; Concha, A.; Gonzalez, M.; Zarzuelo, A.

Infliximab for Crohn's disease
pp. 2041-2042(2)
Authors: Verspaget, H. W.; Van Der Zon, A. M.; Gao, Q.; Van Hogezand, R. A.